Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-020-2279-8 http://scihub22266oqcxt.onion/10.1038/s41586-020-2279-8 32349121!7332423!32349121     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2020 ; 582 (7811): 277-282 Nephropedia Template TP {{tp|p=32349121|t=2020. Massively multiplexed nucleic acid detection with Cas13 |pdf=|usr=}}{{32349121}} gab.com Text Massively multiplexed nucleic acid detection with Cas13 JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=32349121 #FOAvip The great majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3) while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanolitre droplets containing CRISPR-based nucleic acid detection reagents(7) self-organize in a microwell array(8) to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of more than 4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with at least 10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. The intrinsic multiplexing and throughput capabilities of CARMEN make it practical to scale, as miniaturization decreases reagent cost per test by more than 300-fold. Scalable, highly multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11). Twit Text FOAVip Massively multiplexed nucleic acid detection with Cas13 ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=32349121 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32349121 #FOAvip English Wikipedia <ref>{{Cite pmid|32349121}}</ref> Massively multiplexed nucleic acid detection with Cas13 #MMPMID32349121 Ackerman CM; Myhrvold C; Thakku SG; Freije CA; Metsky HC; Yang DK; Ye SH; Boehm CK; Kosoko-Thoroddsen TF; Kehe J; Nguyen TG; Carter A; Kulesa A; Barnes JR; Dugan VG; Hung DT; Blainey PC; Sabeti PC Nature 2020[Jun]; 582 (7811): 277-282 PMID32349121show ga The great majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3) while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanolitre droplets containing CRISPR-based nucleic acid detection reagents(7) self-organize in a microwell array(8) to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of more than 4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with at least 10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. The intrinsic multiplexing and throughput capabilities of CARMEN make it practical to scale, as miniaturization decreases reagent cost per test by more than 300-fold. Scalable, highly multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11). |Animals[MESH] |Betacoronavirus/genetics/isolation & purification[MESH] |CRISPR-Associated Proteins/*metabolism[MESH] |CRISPR-Cas Systems/*genetics[MESH] |Drug Resistance, Viral/genetics[MESH] |Genome, Viral/genetics[MESH] |HIV/classification/genetics/isolation & purification[MESH] |Humans[MESH] |Influenza A virus/classification/genetics/isolation & purification[MESH] |Microfluidic Analytical Techniques/instrumentation/*methods[MESH] |RNA, Guide, CRISPR-Cas Systems/genetics[MESH] |SARS-CoV-2[MESH] |Sensitivity and Specificity[MESH]Massively multiplexed nucleic acid detection with Cas13 (epmc).pdf DeepDyve Pubget Overpricing